董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer Bath | 女 | CEO, President and Director | -- | 115.79万美元 | 未持股 | 2025-07-29 |
| Kamil Isaev | 男 | Director | -- | 未披露 | 未持股 | 2025-07-29 |
| Dirk Witters | 男 | Chair of the Board and Director | -- | 9.46万美元 | 未持股 | 2025-07-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer Bath | 女 | CEO, President and Director | -- | 115.79万美元 | 未持股 | 2025-07-29 |
| Ilse Roodink | 女 | CSO | -- | 48.21万美元 | 未持股 | 2025-07-29 |
| Joseph Scheffler | 男 | Interim CFO | -- | 14.69万美元 | 未持股 | 2025-07-29 |
| Kari Graber | 女 | Vice President of Commercial Services | -- | 39.39万美元 | 未持股 | 2025-07-29 |
董事简历
中英对照 | 中文 | 英文- Jennifer Bath
-
詹妮弗·巴斯（Jennifer Bath），在生物制药行业拥有二十年的经验，此前曾在Aldevron，LLC的执行团队任职。此前，她是全球疫苗研究所的执行董事，曾担任国际顾问，在战略规划和企业增长以及将制药公司的科学挑战转化为运营解决方案方面拥有经验丰富且经过验证的领导者。巴斯博士专注于战略增长、业务运营调整和价值创造。她拥有北达科他州立大学细胞和分子生物学博士学位。
Jennifer Bath,is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. There, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology, and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives. - 詹妮弗·巴斯（Jennifer Bath），在生物制药行业拥有二十年的经验，此前曾在Aldevron，LLC的执行团队任职。此前，她是全球疫苗研究所的执行董事，曾担任国际顾问，在战略规划和企业增长以及将制药公司的科学挑战转化为运营解决方案方面拥有经验丰富且经过验证的领导者。巴斯博士专注于战略增长、业务运营调整和价值创造。她拥有北达科他州立大学细胞和分子生物学博士学位。
- Jennifer Bath,is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. There, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology, and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.
- Kamil Isaev
-
Kamil Isaev，在AI、半导体技术和全球研发运营方面拥有超过30年的专业知识，曾在英特尔、戴尔EMC、阿莱技术、ABRT VC担任领导职务。Isaev先生目前担任ABRT VC的风险合伙人，领导ABRT AI Lab和VC Score项目，开发人工智能驱动的评估模型，以评估和排名人工智能初创公司，为投资者提供数据驱动的洞察力，以识别高潜力机会。他在ABRT VC的角色专注于将前沿人工智能研究与商业化战略联系起来，帮助人工智能驱动的公司完善其进入市场的方法并最大限度地提高可扩展性。Isaev先生还是IEEE的成员，也是一流大学的客座讲师，并且经常在人工智能和半导体行业会议上发表演讲。他拥有莫斯科国立大学物理学（等离子体物理和等离子体化学）理学硕士和博士学位，并在等离子体物理和半导体技术方面撰写了30多篇科学出版物。
Kamil Isaev,has over 30 years of expertise in AI, semiconductor technologies, and global R&D operations, and has held leadership roles at Intel, Dell EMC, Align Technology, and ABRT VC. Mr. Isaev currently serves as a Venture Partner at ABRT VC, where he leads the ABRT AI Lab and the VC Score project, developing AI-powered evaluation models to assess and rank AI startups, providing investors with data-driven insights to identify high-potential opportunities. His role at ABRT VC is focused on bridging cutting-edge AI research with commercialization strategies, helping AI-driven companies refine their go-to-market approach and maximize scalability. .Mr. Isaev is also a member of IEEE, a guest lecturer at leading universities, and a frequent speaker at AI and semiconductor industry conferences. He holds an MSc and PhD in Physics (Plasma Physics and Plasma Chemistry) from Moscow State University and has authored over 30 scientific publications in plasma physics and semiconductor technology. - Kamil Isaev，在AI、半导体技术和全球研发运营方面拥有超过30年的专业知识，曾在英特尔、戴尔EMC、阿莱技术、ABRT VC担任领导职务。Isaev先生目前担任ABRT VC的风险合伙人，领导ABRT AI Lab和VC Score项目，开发人工智能驱动的评估模型，以评估和排名人工智能初创公司，为投资者提供数据驱动的洞察力，以识别高潜力机会。他在ABRT VC的角色专注于将前沿人工智能研究与商业化战略联系起来，帮助人工智能驱动的公司完善其进入市场的方法并最大限度地提高可扩展性。Isaev先生还是IEEE的成员，也是一流大学的客座讲师，并且经常在人工智能和半导体行业会议上发表演讲。他拥有莫斯科国立大学物理学（等离子体物理和等离子体化学）理学硕士和博士学位，并在等离子体物理和半导体技术方面撰写了30多篇科学出版物。
- Kamil Isaev,has over 30 years of expertise in AI, semiconductor technologies, and global R&D operations, and has held leadership roles at Intel, Dell EMC, Align Technology, and ABRT VC. Mr. Isaev currently serves as a Venture Partner at ABRT VC, where he leads the ABRT AI Lab and the VC Score project, developing AI-powered evaluation models to assess and rank AI startups, providing investors with data-driven insights to identify high-potential opportunities. His role at ABRT VC is focused on bridging cutting-edge AI research with commercialization strategies, helping AI-driven companies refine their go-to-market approach and maximize scalability. .Mr. Isaev is also a member of IEEE, a guest lecturer at leading universities, and a frequent speaker at AI and semiconductor industry conferences. He holds an MSc and PhD in Physics (Plasma Physics and Plasma Chemistry) from Moscow State University and has authored over 30 scientific publications in plasma physics and semiconductor technology.
- Dirk Witters
-
德克·维特斯（Dirk Witters）于2019年创立了Conanti Consult BV，这是一家咨询精品店，除其他外，他在该公司就收购和融资转让的执行提供建议。在此之前，Witters先生还曾在2019年7月至2020年3月期间担任私募股权投资公司New Rhein Healthcare Investors创始人的顾问。此外，Witters先生于2018年12月至2019年6月担任KBC集团可持续金融项目管理办公室主任；并于2020年6月至2022年4月担任BioStrand BV董事会主席。
Dirk Witters,founded Conanti Consult BV in 2019, an advisory boutique, where he, among other things, advises on the execution of acquisitions and capital raising assignments. Prior to that, Mr. Witters also served as an advisor to the founder of New Rhein Healthcare Investors, a private equity investment firm from July 2019 to March 2020. In addition, Mr. Witters was the Director Program Management Office, Sustainable Finance for KBC Group from December 2018 to June 2019; and the president of the Board of BioStrand BV from June 2020 to April 2022. - 德克·维特斯（Dirk Witters）于2019年创立了Conanti Consult BV，这是一家咨询精品店，除其他外，他在该公司就收购和融资转让的执行提供建议。在此之前，Witters先生还曾在2019年7月至2020年3月期间担任私募股权投资公司New Rhein Healthcare Investors创始人的顾问。此外，Witters先生于2018年12月至2019年6月担任KBC集团可持续金融项目管理办公室主任；并于2020年6月至2022年4月担任BioStrand BV董事会主席。
- Dirk Witters,founded Conanti Consult BV in 2019, an advisory boutique, where he, among other things, advises on the execution of acquisitions and capital raising assignments. Prior to that, Mr. Witters also served as an advisor to the founder of New Rhein Healthcare Investors, a private equity investment firm from July 2019 to March 2020. In addition, Mr. Witters was the Director Program Management Office, Sustainable Finance for KBC Group from December 2018 to June 2019; and the president of the Board of BioStrand BV from June 2020 to April 2022.
高管简历
中英对照 | 中文 | 英文- Jennifer Bath
詹妮弗·巴斯（Jennifer Bath），在生物制药行业拥有二十年的经验，此前曾在Aldevron，LLC的执行团队任职。此前，她是全球疫苗研究所的执行董事，曾担任国际顾问，在战略规划和企业增长以及将制药公司的科学挑战转化为运营解决方案方面拥有经验丰富且经过验证的领导者。巴斯博士专注于战略增长、业务运营调整和价值创造。她拥有北达科他州立大学细胞和分子生物学博士学位。
Jennifer Bath,is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. There, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology, and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.- 詹妮弗·巴斯（Jennifer Bath），在生物制药行业拥有二十年的经验，此前曾在Aldevron，LLC的执行团队任职。此前，她是全球疫苗研究所的执行董事，曾担任国际顾问，在战略规划和企业增长以及将制药公司的科学挑战转化为运营解决方案方面拥有经验丰富且经过验证的领导者。巴斯博士专注于战略增长、业务运营调整和价值创造。她拥有北达科他州立大学细胞和分子生物学博士学位。
- Jennifer Bath,is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. There, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology, and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.
- Ilse Roodink
Ilse Routink，自2021年7月1日起担任公司CSO，支持公司的全球研发团队。在被任命为CSO之前，她曾于2013年至2021年在该公司位于OSS的荷兰工厂担任不同的科学职务。在她最后一次担任IPA Europe科学总监期间，Routink博士负责监督合同研究项目的执行和管理，并积极参与支持抗体表征和工程的创新技术的整合。自2019年成立以来，Routink博士一直担任Talem Therapeutics科学咨询委员会主席，领导Talem管道资产的开发。Routink博士毕业于荷兰奈梅亨Radboud大学，获得生物医学Health Sciences硕士学位和医学科学博士学位。她的工作产生了几篇同行评审的出版物，专注于平台开发，以促进发现专门识别原生肿瘤靶点的抗体。
Ilse Roodink,serves as CSO of IPA, supporting the company's global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company's Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of IPA Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics' Scientific Advisory Committee, leading the development of Talem's pipeline assets. Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master's degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.- Ilse Routink，自2021年7月1日起担任公司CSO，支持公司的全球研发团队。在被任命为CSO之前，她曾于2013年至2021年在该公司位于OSS的荷兰工厂担任不同的科学职务。在她最后一次担任IPA Europe科学总监期间，Routink博士负责监督合同研究项目的执行和管理，并积极参与支持抗体表征和工程的创新技术的整合。自2019年成立以来，Routink博士一直担任Talem Therapeutics科学咨询委员会主席，领导Talem管道资产的开发。Routink博士毕业于荷兰奈梅亨Radboud大学，获得生物医学Health Sciences硕士学位和医学科学博士学位。她的工作产生了几篇同行评审的出版物，专注于平台开发，以促进发现专门识别原生肿瘤靶点的抗体。
- Ilse Roodink,serves as CSO of IPA, supporting the company's global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company's Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of IPA Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics' Scientific Advisory Committee, leading the development of Talem's pipeline assets. Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master's degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.
- Joseph Scheffler
Joseph Scheffler担任IPA的临时CFO，负责监督财务战略和报告，以确保遵守法规，优化资本配置以支持增长，并提供财务领导。他此前曾任职于安永，曾担任CFO、财务副总裁和公司财务主管等高管职务。他的背景包括30年的经验，将上市公司运营与成功的初创企业融为一体。他拥有芝加哥洛约拉大学会计学学士学位和MBA学位，主修金融和战略管理。
Joseph Scheffler,serves as the interim CFO for IPA and is responsible for overseeing the financial strategy and reporting to ensure compliance with regulations, optimizing capital allocation to support growth, and providing financial leadership. He previously worked for Ernst & Young and has held executive positions of CFO, Vice President of Finance and Corporate Treasurer. His background includes 30 years of experience and blends publicly traded company operations with successful startup ventures. He holds a BS degree in Accounting and an MBA, with concentrations in Finance and Strategic Management, from the Loyola University of Chicago.- Joseph Scheffler担任IPA的临时CFO，负责监督财务战略和报告，以确保遵守法规，优化资本配置以支持增长，并提供财务领导。他此前曾任职于安永，曾担任CFO、财务副总裁和公司财务主管等高管职务。他的背景包括30年的经验，将上市公司运营与成功的初创企业融为一体。他拥有芝加哥洛约拉大学会计学学士学位和MBA学位，主修金融和战略管理。
- Joseph Scheffler,serves as the interim CFO for IPA and is responsible for overseeing the financial strategy and reporting to ensure compliance with regulations, optimizing capital allocation to support growth, and providing financial leadership. He previously worked for Ernst & Young and has held executive positions of CFO, Vice President of Finance and Corporate Treasurer. His background includes 30 years of experience and blends publicly traded company operations with successful startup ventures. He holds a BS degree in Accounting and an MBA, with concentrations in Finance and Strategic Management, from the Loyola University of Chicago.
- Kari Graber
Kari Graber，担任IPA商业服务副总裁，负责在整个IPA全球公司家族中全面领导和实施项目管理计划。她在为各食品制造商开发、实施和指导实验室操作、质量保证、法规遵从性以及供应链管理计划方面拥有超过20年的经验，并在一家巴氏杀菌/灭菌技术和设备供应商担任了五年的销售和技术总监。在加入IPA之前，Graber女士曾在Aldevron LLC任职，担任其抗体服务平台的客户关系管理职务。她拥有食品科学与技术理学学士学位和微生物学辅修学位。
Kari Graber,serves as the Vice President of Commercial Services for IPA and is responsible for the overall leadership and implementation of the Project Management program throughout IPA's global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining IPA, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.- Kari Graber，担任IPA商业服务副总裁，负责在整个IPA全球公司家族中全面领导和实施项目管理计划。她在为各食品制造商开发、实施和指导实验室操作、质量保证、法规遵从性以及供应链管理计划方面拥有超过20年的经验，并在一家巴氏杀菌/灭菌技术和设备供应商担任了五年的销售和技术总监。在加入IPA之前，Graber女士曾在Aldevron LLC任职，担任其抗体服务平台的客户关系管理职务。她拥有食品科学与技术理学学士学位和微生物学辅修学位。
- Kari Graber,serves as the Vice President of Commercial Services for IPA and is responsible for the overall leadership and implementation of the Project Management program throughout IPA's global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining IPA, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.